Franklin Genomic Advancements ETF
HELX
9 hedge funds and large institutions have $4.12M invested in Franklin Genomic Advancements ETF in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
17% more capital invested
Capital invested by funds: $3.53M → $4.12M (+$590K)
13% more funds holding
Funds holding: 8 → 9 (+1)
1.89% less ownership
Funds ownership: 81.51% → 79.62% (-1.9%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$185K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$22.9K |
| 3 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$3.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$249K |
| 2 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$44.7K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$2.46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.88M | -$249K | -5,568 | -13% |
|
|
2
Commonwealth Equity Services
Waltham,
Massachusetts
| $845K | -$2.46K | -55 | -0.3% |
|
|
FTUS
3
Flow Traders U.S.
New York
| $348K | – | – | – |
|
|
APA
4
American Portfolios Advisors
Holbrook,
New York
| $296K | – | – | – |
|
|
5
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $214K | +$185K | +4,140 | New |
|
|
BFEC
6
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $197K | +$3.58K | +80 | +2% |
|
|
HI
7
Harbour Investments
Madison,
Wisconsin
| $179K | – | – | – |
|
|
SWM
8
Spire Wealth Management
Mclean,
Virginia
| $88K | -$44.7K | -1,000 | -37% |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| $81K | +$22.9K | +512 | +48% |
|
HELX Hedge Fund Activity: Q2 2021 in Review
9 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2021, worth a combined $4.12M — up 17% from $3.53M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new HELX positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $185K. The largest seller was Jane Street, cutting an estimated $249K.
- 9 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2021, up from 8 in Q1 2021.
- Funds reported $4.12M of Franklin Genomic Advancements ETF stock for Q2 2021, up 17% quarter-over-quarter.
- 1 fund opened new Franklin Genomic Advancements ETF positions in Q2 2021 and 0 closed out, a net change of +1 holder.
- The largest Franklin Genomic Advancements ETF buyer in Q2 2021 was Cambridge Investment Research Advisors, an estimated $185K added.
- The largest Franklin Genomic Advancements ETF seller in Q2 2021 was Jane Street, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2021.